Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases-Reference-Cited by-同舟云学术

Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases

Published:2019-05-06 Issue:10 Volume:19 Page:1001-1014
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Edwards Christopher J.¹,Hercogová Jana²,Albrand Helene³,Amiot Aurelian⁴^ORCID

Affiliation:

1. NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK

2. Dermatology Department, 2nd Medical faculty, Charles University and Na Bulovce Hospital, Prague, Czech Republic

3. Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland

4. Department of Gastroenterology and EC2M3-EA7375 Unit, Assistance Publique-Hôpitaux de Paris, Paris Est Creteil University, Henri Mondor Hospital, Creteil, France

Funder

Fresenius Kabi

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://tandfonline.com/doi/pdf/10.1080/14712598.2019.1610381

Reference108 articles.

1. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

2. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

3. Access to biologicals in Crohn’s disease in ten European countries

4. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

5. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID;Therapeutic Advances in Gastroenterology;2024-01

2. Facilitating pharmacy staff's conversations about non-medical medication switches: Development and testing of a communication training;Research in Social and Administrative Pharmacy;2023-05

3. An Update on Biosimilars in Rheumatic and Musculoskeletal Disorders;Rheumatology;2023

5. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems;Seminars in Arthritis and Rheumatism;2022-02